Learn: FDA Drug Regulatory Intelligence
Educational guides on the regulatory frameworks, patent strategies, and competitive dynamics that shape the U.S. pharmaceutical market.
What is the FDA Orange Book?
A complete guide to the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations — the foundational database for generic drug competition.
Patent Cliffs and Loss of Exclusivity
Understand how patent expirations trigger revenue cliffs for brand-name drugs and create market entry windows for generic competitors.
Skinny Labels and Section VIII Carve-Outs
Learn how generic companies use Section viii carve-outs to launch products before all Orange Book patents expire by omitting patented indications.
The Hatch-Waxman Act and ANDA Litigation
A guide to Paragraph IV certifications, 30-month stays, 180-day exclusivity, and the patent challenge framework that shapes generic drug entry.